LEADER 00000cam  2200481Mu 4500 
001    747410807 
003    OCoLC 
005    20200403072125.9 
006    m     o  d         
007    cr |n|---||||| 
008    110822s2011    xx      o     000 0 eng d 
020    9781439849620 
020    1439849625 
035    (OCoLC)747410807 
035    Ebook Central DDA Titles 
035    skip4alma 
040    EBLCP|beng|epn|cEBLCP|dOCLCQ|dIDEBK|dOCLCQ|dOCLCO|dDEBSZ
       |dOCLCA|dOCLCQ|dMERUC|dUAB|dOCLCF|dOCLCO|dOCLCQ|dOCLCO
       |dOCLCQ|dINT|dOCLCQ|dYDX|dOCLCQ|dAU@|dOCLCQ|dUKAHL 
049    txum 
050  4 R853.C55 .C46 2011eb 
100 1  Chow, Shein-Chung. 
245 10 Controversial Statistical Issues in Clinical Trials. 
260    Hoboken :|bChapman & Hall/CRC,|c2011. 
300    1 online resource (598 pages) 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
490 1  Chapman & Hall/CRC Biostatistics Series 
505 0  Front Cover -- Contents -- Preface -- Chapter 1: 
       Introduction -- Chapter 2: Good Statistical Practices -- 
       Chapter 3: Bench-to-Bedside Translational Research -- 
       Chapter 4: Bioavailability and Bioequivalence -- Chapter 5
       : Hypotheses for Clinical Evaluation and Significant 
       Digits -- Chapter 6: Instability of Sample Size 
       Calculation -- Chapter 7: Integrity of Randomization/
       Blinding -- Chapter 8: Clinical Strategy for Endpoint 
       Selection -- Chapter 9: Protocol Amendments -- Chapter 10:
       Seamless Adaptive Trial Designs -- Chapter 11: 
       Multiplicity in Clinical Trials -- Chapter 12: 
       Independence of Data Monitoring Committee -- Chapter 13: 
       Two-Way ANOVA versus One-Way ANOVA with Repeated Measures 
       -- Chapter 14: Validation of QOL Instruments -- Chapter 15
       : Missing Data Imputation -- Chapter 16: Center Grouping -
       - Chapter 17: Non-Inferiority Margin -- Chapter 18: QT 
       Studies with Recording Replicates -- Chapter 19: 
       Multiregional Clinical Trials -- Chapter 20: Dose 
       Escalation Trials -- Chapter 21: Enrichment Process in 
       Target Clinical Trials -- Chapter 22: Clinical Trial 
       Simulation -- Chapter 23: Traditional Chinese Medicine -- 
       Chapter 24: The Assessment of Follow-On Biologic Products 
       -- Chapter 25: Generalizability/Reproducibility 
       Probability -- Chapter 26: Good Review Practices -- 
       Chapter 27: Probability of Success -- References -- Back 
       Cover. 
506    Available only to authorized UTEP users. 
520    In clinical trial practice, controversial statistical 
       issues inevitably occur regardless of the compliance with 
       good statistical practice and good clinical practice. But 
       by identifying the causes of the issues and correcting 
       them, the study objectives of clinical trials can be 
       better achieved. Controversial Statistical Issues in 
       Clinical Trials covers commonly encountered controversial 
       statistical issues in clinical trials and, whenever 
       possible, makes recommendations to resolve these problems.
       The book focuses on issues occurring at various stages of 
       clinical research and development, includi. 
588 0  Print version record. 
650  0 Drugs|xTesting. 
650  0 Drug development. 
650  0 Clinical trials. 
776 08 |iPrint version:|aChow, Shein-Chung.|tControversial 
       Statistical Issues in Clinical Trials.|dHoboken : Chapman 
       & Hall/CRC, ©2011|z9781439849613 
830  0 Chapman & Hall/CRC biostatistics series. 
856 40 |uhttp://0-ebookcentral.proquest.com.lib.utep.edu/lib/utep
       /detail.action?docID=762509|zTo access this resource 
LOCATION CALL # STATUS
 Internet  Electronic Book    AVAILABLE